Sign in
CompletedPhase 2

Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Key facts

Who runs it
Xeris Pharmaceuticals
Where
Chula Vista, Miami Lakes, Montclair, Renton, San Antonio, and Sugar Land, United StatesSee the 6 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
46 people enrolled
Started
15 May 2023
Ended
22 Feb 2024
Type of study
Interventional
Treatments tested
  • levothyroxine sodium
Record updated
3 July 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Provide written informed consent
  • Male or female between the ages of 18 and 65 years (inclusive) at Screening, with chronic hypothyroidism and on a stable dose of oral levothyroxine (Synthroid or an FDA-approved generic equivalent to Synthroid) or, if in the pharmacokinetic substudy, Synthroid only for at least 3 months
  • Thyroid stimulating hormone (TSH) within the normal range at Screening (central laboratory) and at least 3 months prior to Screening (documented by local laboratory)
  • Free thyroxine within the normal range at Screening (central laboratory)

Who cannot take part

  • History of hypersensitivity to levothyroxine (any formulation)
  • Current dose of oral levothyroxine, based on body weight >2 μg/kg/day
  • Current levothyroxine total daily dose either <50 μg or >375 μg
  • Current use of combined thyroid treatment (i.e., Synthroid plus liothyronine or Synthroid plus Armour Thyroid) and/or any other levothyroxine aside from those used in the study

Where in United States

  • ProSciento, Inc.Chula Vista, United States
  • Panax Clinical Research, LLCMiami Lakes, United States
  • Catalina Research Institute, L.L.C.Montclair, United States
  • Rainier Clinical Research CenterRenton, United States
  • American Research CorporationSan Antonio, United States
  • Mt Olympus Medical Research, LLCSugar Land, United States

About the trial

What the trial wants to find out

This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121 (levothyroxine sodium) in patients with hypothyroidism and to assess the safety and tolerability of XP-8121(levothyroxine sodium) after once weekly subcutaneous injections. This study includes the following periods: Screening, Titration Period, and Maintenance Period. The study will conclude with an End of Maintenance Visit or Early Termination (ET) Visit.

The group in the trial

  • XP-8121Treatment being tested

    XP-8121 100 to 1500 μg subcutaneous injection

    Treatment: levothyroxine sodium

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2, Multicenter, Non-Randomized, Open-Label, Single Arm, Self-controlled Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Record updated
3 July 2025